Slides
Page 1
First Quarter Fiscal 2027 Results August 6 , 2026 © 2026 Haemonetics Corporation HAEMONETICS®
Page 2
2 Q1 Fiscal 2027 Conference Call Detail Conference call will take place at 8:00 a.m. ET on August 6, 2026, and can be accessed via live webcast: Link or teleconference : Link . The earnings release, accompanying slides and a replay of the conference call (beginning at 11:00 a.m. ET) are available online at www.haemonetics.com . CONFERENCE CALL SPEAKERS Chris Simon President & CEO James D’Arecca EVP, Chief Financial Officer Olga Guyette VP, Investor Relations & Treasury
Page 3
3 Important Information Safe Harbor for Forward - Looking Statements This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Sectio n 21E of the Securities Exchange Act of 1934. Forward - looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as “may,” “will,” “should,” “co uld ,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “forecasts,” “foresees,” “potential” and other words of similar meaning in conjunction with statements regarding, among other th ings, ( i ) plans and objectives of management for operations of Haemonetics Corporation (“Haemonetics” or the “Company”), including plans or objectives related to the Company’s strategy for growth; pro duc t development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company’s market and regional alignmen t i nitiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company’s share repurchase pr ogr am; and (iii) the assumptions underlying or relating to any statement described in points ( i ) and (ii) above. Such forward - looking statements are not meant to predict or guarantee actual results, performance, events or c ircumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a numbe r o f risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward - looking statements as a result of the se risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward - looking statements or cause actual results to differ m aterially from expected or desired results can be found in the Company’s most recent Annual Report on Form 10 - K and Quarterly Reports on Form 10 - Q filed or to be filed with the U.S. Securities Exchange Comm ission (the “SEC”) under the headings “Risk Factors” and “Cautionary Statement Regarding Forward - Looking Information” and in the Company’s other periodic filings with the SEC. The Company does not undertake to update these forward - looking statements. Non - GAAP Financial Measures This presentation contains non - GAAP financial measures as defined under applicable SEC rules and regulations. These non - GAAP fin ancial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. We strongly encourage investors to review the Co mpany’s financial statements and publicly - filed reports in their entirety and not rely on any single financial measure. Because non - GAAP financial measures are not standardized, it may not be possible to compar e these financial measures to similarly titled measures used by other companies. To the extent available without unreasonable effort, we have provided reconciliations of these non - GAAP measures to their most c omparable GAAP measure in the appendix to this presentation, which is available on our website at www.haemonetics.com. Except with respect to organic revenue growth guidance, the Company does not provide a re conciliation of forward - looking non - GAAP measures because certain significant information necessary for such reconciliations are unavailable, dependent on future events outside of our control an d cannot be predicted without unreasonable efforts. When used in this presentation, organic revenue growth excludes the impact of currency fluctuation and the exit of certain li qui d solution products. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted interest and other income/expense, adjusted provision for income taxes, adjusted net income and ad jus ted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, amortization of fair value inventory step - up, a cquisition, integration and divestiture related costs, certain tax settlements, unusual or infrequent and material litigation - related charges, equity method losses, and remeasurement of contingent consideration. Adjuste d net income and adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre - tax adjustm ents occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of the proceeds from the sale of property, plant and eq uip ment. Use of Document This presentation contains certain highlights with respect to our first quarter of fiscal 2027 performance and developments a nd does not purport to be a complete summary thereof. Accordingly, we encourage you to read our earnings release for the first quarter ended June 27, 2026 located in the investor relations section of our websi te at www.haemonetics.com and our Quarterly Report on Form 10 - Q for the quarter ended June 27, 2026 filed with the SEC.
Page 4
4 Q1 Fiscal 2027 Highlights 1) Trailing twelve months. 2) Includes $50 million repayment in Q1 and an additional $50 million repayment in Q2. Broad - based Profitable Growth Executing Our Strategy Building a Higher - quality Business All three growth platforms contributed to 6% organic revenue and 4% adjusted earnings growth Raised FY27 guidance following strong Q1 performance Accelerating Persona ® PLUS adoption strengthens the NexSys PCS® platform Interventional Technologies returns to growth; VASCADE MVP® XL system label helps accelerate momentum Blood Management Technologies continues to demonstrate durable growth across the franchise Multiple growth platforms are driving a more durable growth profile Continued strong cash generation enabled repayment of $100 million on the revolving credit facility 2 Differentiated innovation continues to expand long - term growth opportunities Strong cash generation with Q1 free cash flo w increasing ~15X YoY , and TTM 1 free cash flow conversion of 106%
Page 5
Q1 FY'26 Q1 FY'27 5 Q1 Fiscal 2027 Revenue by Business Unit 1) Includes the impact of the exit of certain liquid solution products and nominal historical pre - acquisition revenue of Vivasure . 2) Other includes blood collection and processing devices and disposables. 3) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the MedSurg business unit. 4) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit. REVENUE (in millions) Apheresis MedSurg $321 $339 Q1 2027 Plasma $155.5 $145.1 7.2% 8.2% Other 2 $35.8 $36.7 (2.4%) (2.8%) Apheresis $191.3 $181.7 5.3% 6.0% Interventional Technologies 3 $59.9 $58.5 2.5% 2.8% Blood Management Technologies 4 $88.1 $81.2 8.6% 8.1% MedSurg $148.1 $139.7 6.0% 5.9% Total Net Revenues $339.4 $321.4 5.6% 5.9% Q1 2026 REPORTED GROWTH ORGANIC GROWTH 1 (in millions)
Page 6
Q1 Fiscal 2027 Financial Review 6 Gross Margin % 59.8% 59.8% - bps Operating Margin % 16.9% 16.8% +10bps Net Income Margin % 9.7% 10.6% - 90bps Income Tax Rate 30.6% 24.7% +590bps Earnings Per Share $0.72 $0.70 3% Q1 2027 Adjusted Gross Margin % 60.4% 60.8% - 40bps Adjusted Operating Margin % 23.4% 24.1% - 70bps Adjusted Net Income Margin % 15.4% 16.6% - 120bps Adjusted Income Tax Rate 25.7% 24.9% +80bps Adjusted Earnings Per Share $1.14 $1.10 4% GAAP RESULTS NON - GAAP RESULTS Q1 2026 Y/Y Q1 2027 Q1 2026 Y/Y
Page 7
Q1 Fiscal 2027 Segment Performance 7 1) Certain corporate expenses and amounts considered to be non - recurring or non - operational are excluded from segment operating income. These items include acquisition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, di gital transformation costs related to the upgrade of the Company’s enterprise resource planning system, unusual or infrequent and material litigation - related charges and gains, losses o n dispositions and sale of assets, remeasurement of the contingent consideration and unusual or infrequent gains such as on repurchases of convertible notes or divestitures. Total corporate and unallocated expenses were $21.8M in Q1 FY’27 and $23.7M in Q1 FY’26. Please refer to the reconciliation table in Appendix D of this presentation for mo re information. APHERESIS Revenue $191.3M $181.7M 5.3% reported / 6.0% organic Adjusted Operating Margin % ¹ 29.6% 32.6% - 300bps MEDSURG Revenue $148.1M $139.7M 6.0% reported / 5.9% organic Adjusted Operating Margin % ¹ 15.3% 13.2% +210bps Q1 2027 Q1 2026 Y/Y Q1 2027 Q1 2026 Y/Y
Page 8
Q1 FY27 Q1 FY'26 Q1 FY'27 TTM Q1 FY'26 TTM 8 Balance Sheet and Cash Flow Metrics 1) Net debt is calculated as total debt minus cash & cash equivalents. 2) Available borrowing capacity under the existing rev olv ing credit facility minus any eligible letters of credit. 3) Gross and net leverage ratios per the terms set forth in the Company’s existing credit agreement. 4) Includes capi tal expenditures, non - cash inventory transfers of Haemonetics equipment and proceeds from the sale of property, plant and equipment. CASH FROM OPERATIONS (dollars in millions) 75% 5% 106% 62% Free cash flow to adjusted net income ratio $52 $17 $328 $227 $39 $13 $2 $15 $247 $81 $164 $63 FCF CapEx & Other 4 6/27/26 3/28/26 (in millions) Cash & cash equivalents $223 $245 Working capital $548 $552 Total debt $1,174 $1,225 Net debt 1 $951 $980 Available credit 2 $749 $749 Gross leverage ratio 3 2.82 2.97 Net leverage ratio 3 2.69 2.73
Page 9
9 Full - Year Fiscal 2027 Guidance 1) Organic revenue growth guidance excludes the impact of currency fluctuation and the exit of certain liquid solution produc ts. Organic growth guidance also includes nominal historical pre - acquisition revenue of Vivasure to provide a comparable view of period - over - period performance. 2) Free cash flow conversion is calculated as free cash flow divided by adjusted net income. 3) Recast as of June 5, 2026 ann oun cement of updates to financial reporting segments solely to align previously issued guidance with the new reportable segment structure. GUIDANCE AS OF MAY 7, 2026 3 GUIDANCE AS OF AUGUST 6, 2026 Reported Revenue 4 – 7% 5 – 8% 53rd Week Impact (~2%) (~2%) Currency Impact 0 – 1% 0 – 1% Organic Revenue 1 3 – 6% 4 – 7% Apheresis LSD Growth LSD to MSD Growth MedSurg MSD Growth MSD Growth Adjusted Operating Margin 50 – 100 bps expansion YoY 50 – 100 bps expansion YoY Adjusted EPS Comparable to reported revenue growth Comparable to reported revenue growth Free cash flow conversion 2 ~80% ~80%
Page 10
© 2026 Haemonetics Corporation Appendices
Page 11
11 Appendix A: Reconciliation of GAAP to Organic Revenue Growth Rates ($ millions) Q1 2027 Q1 2026 Reported growth Currency impact Acquisitions & Divestitures 1 Organic growth 2 Plasma $155.5 $145.1 7.2% 0.1% (1.1%) 8.2% Other 3 $35.8 $36.7 (2.4%) 0.4% – (2.8%) Apheresis $191.3 $181.7 5.3% 0.2% (0.9%) 6.0% Interventional Technologies 4 $59.9 $58.5 2.5% (0.3%) – 2.8% Blood Management Technologies 5 $88.1 $81.2 8.6% 0.5% – 8.1% MedSurg $148.1 $139.7 6.0% 0.1% – 5.9% Total Net Revenues $339.4 $321.4 5.6% 0.2% (0.5%) 5.9% 1) Includes the impact of the exit of certain liquid solution products. 2) Includes nominal historical pre - acquisition revenue o f Vivasure . 3) Other includes blood collection and processing devices and disposables. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Eso phageal Protection product lines of the MedSurg business unit. 4) Blood Management Technologies includes Hemostasis Management, Cell Salvage, and Transfusion Management prod uct lines of the MedSurg business unit.
Page 12
12 Appendix B: Reconciliation of GAAP to Non - GAAP Q1 Fiscal 2027 Financial Results ($ millions) Gross profit Operating expenses Operating income Interest and other income (expense) Provision (benefit) for income taxes Net income Earnings per diluted share Reported $202.8 $145.3 $57.5 ($9.9) $14.6 $33.0 $0.72 Amortization of acquired intangible assets – ($10.2) $10.2 – $2.3 $7.9 $0.16 Integration and transaction costs $1.3 ($1.4) $2.7 – ($0.4) $3.1 $0.07 Restructuring costs $0.8 ($1.5) $2.3 – $0.5 $1.8 $0.04 Restructuring related costs – $0.1 – – – – – Digital transformation costs – ($6.2) $6.2 – $1.6 $4.6 $0.10 Litigation - related charges Equity method losses Discrete tax items – – – ($0.5) – – $0.5 – – – $1.0 – – $0.3 ($0.7) $0.5 $0.7 $0.7 $0.01 $0.02 $0.02 Adjusted $204.9 $125.6 $79.3 ($8.9) $18.1 $52.3 $1.14 Adjusted, as a percentage of net revenues 60.4% 37.0% 23.4% 15.4%
Page 13
13 Appendix B: Reconciliation of GAAP to Non - GAAP Q1 Fiscal 2026 Financial Results ($ millions) Gross profit Operating expenses Operating income (loss) Interest and other income (expense) Provision for income taxes Net income (loss) Earnings per diluted share Reported $192.2 $138.4 $53.9 ($8.7) $11.1 $34.0 $0.70 Amortization of acquired intangible assets – ($11.4) $11.4 – $2.9 $8.5 $0.18 Amortization of fair value inventory step up $2.4 – $2.4 – $0.6 $1.8 $0.04 Integration and transaction costs $1.0 ($1.7) $2.7 $2.0 $1.2 $3.5 $0.07 Restructuring costs ($0.4) ($1.7) $1.3 – $0.3 $1.0 $0.02 Restructuring related costs – ($0.1) $0.1 – – – – Digital transformation costs – ($5.4) $5.4 – $1.3 $4.0 $0.08 Litigation - related charges – ($0.6) $0.6 – $0.1 $0.4 $0.01 Remeasurement of contingent consideration – $0.1 ($0.1) – – ($0.1) – Adjusted $195.3 $117.8 $77.6 ($6.7) $17.6 $53.2 $1.10 Adjusted, as a percentage of net revenues 60.8% 36.6% 24.1% 16.6%
Page 14
14 Appendix C: Reconciliation of Cash Flows ($ millions) Q1 2027 Q1 2026 Free Cash Flow Reconciliation Cash provided by operating activities $52.3 $17.4 Capital expenditures ($7.9) ($3.8) Additions to Haemonetics equipment ($5.6) ($11.5) Proceeds from sale of property, plant and equipment $0.2 $0.3 Free cash flow $39.1 $2.5
Page 15
15 Appendix D: Reconciliation of Segment Operating Income to the Total Company Net Income (1 of 2) ($ millions) Q1 2027 Q1 2026 Net revenues: Apheresis $191.3 $181.7 MedSurg $148.1 $139.7 Total net revenues $339.4 $321.4 Significant segment expenses and operating performance: Apheresis Cost of goods sold $84.1 $75.9 Selling, general and administrative $44.3 $39.9 Research and development $6.4 $6.8 Apheresis operating income $56.5 $59.2 MedSurg Cost of goods sold $50.4 $50.2 Selling, general and administrative $65.2 $62.3 Research and development $9.8 $8.7 MedSurg operating income $22.7 $18.4
Page 16
16 Appendix D: Reconciliation of Segment Operating Income to the Total Company Net Income (2 of 2) 1) Comprised of litigation - related charges and remeasurement of contingent consideration for the three months ended June 27, 202 6 and June 28, 2025. ($ millions) Q1 2027 Q1 2026 Corporate and unallocated expenses Amortization of acquired assets ($10.2) ($13.8) Integration and transaction costs ($2.7) ($2.7) Restructuring and restructuring related costs ($2.3) ($1.3) Digital transformation costs ($6.2) ($5.4) Other 1 ($0.5) ($0.5) Operating income $57.5 $53.9 Interest and other expense, net ($9.9) ($8.7) Income before provision for income taxes $47.6 $45.2
Page 17
17 Appendix E: Reconciliation of GAAP to Non - GAAP of TTM Financial Results 1 1) Reflects non - GAAP adjustments for each of the four subsequent quarters ending June 27, 2026 and June 28, 2025, respectively. ($ millions) TTM Q1 FY27 Net income (loss) TTM Q1 FY26 Net income (loss) Reported $96.3 $163.3 Amortization of acquired intangible assets $32.6 $35.4 Amortization of fair value inventory step up $2.6 $9.2 Acquisition, Integration, transaction and divestiture costs $12.8 $7.7 Restructuring costs $3.1 $7.9 Restructuring related costs – $3.7 Digital transformation costs $16.9 $14.7 Write downs of certain in - process intangible assets and PCS2 related charges $0.7 $3.0 MDR and IVDR costs – $2.8 Litigation - related charges – $2.0 Impairment of intangible assets $65.3 $1.8 Remeasurement of contingent consideration ($1.5) ($20.8) Provision for pre - acquisition inventory $5.5 – Equity method losses ($0.7) – Discrete tax items ($1.2) $1.7 Adjusted $233.8 $232.4 Adjusted, as a percentage of net revenues 17.3% 17.3% ($ millions) TTM Q1 FY27 TTM Q1 FY26 Free Cash Flow Reconciliation Cash provided by operating activities $328.2 $226.5 Capital expenditures ($36.9) ($37.4) Additions to Haemonetics’ equipment ($46.0) ($28.4) Proceeds from sale of property, plant and equipment $1.3 $3.2 Free cash flow $246.5 $164.0